Wells Fargo & Company Viracta Therapeutics, Inc. Transaction History

Wells Fargo & Company

$407 Billion
Q2 2024

A detailed history of Wells Fargo & Company transactions in Viracta Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 171 shares of VIRX stock, worth $37. This represents 0.0% of its overall portfolio holdings.

Number of Shares

171

Previous 385 55.58%

Holding current value

$37

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$0.5 - $1.17 $107 - $250	-214 Reduced 55.58%	171 $0
Q1 2024 May 10, 2024	BUY	$0.48 - $1.13 $1 - $3	3 Added 0.79%	385 $0
Q4 2023 Feb 09, 2024	BUY	$0.44 - $1.04 $5 - $12	12 Added 3.24%	382 $0
Q3 2023 Nov 13, 2023	BUY	$1.03 - $1.58 $27 - $42	27 Added 7.87%	370 $0
Q2 2023 Aug 15, 2023	BUY	$0.89 - $2.13 $7 - $17	8 Added 2.39%	343 $0
Q1 2023 May 12, 2023	BUY	$1.38 - $2.29 $4 - $6	3 Added 0.9%	335 $0
Q4 2022 Feb 13, 2023	BUY	$1.26 - $4.38 $7 - $26	6 Added 1.84%	332 $0
Q3 2022 Nov 14, 2022	BUY	$3.32 - $5.69 $76 - $130	23 Added 7.59%	326 $2,000
Q2 2022 Aug 12, 2022	SELL	$1.87 - $5.0 $121,046 - $323,655	-64,731 Reduced 99.53%	303 $1,000
Q1 2022 May 16, 2022	SELL	$2.23 - $4.76 $24,139 - $51,527	-10,825 Reduced 14.27%	65,034 $310,000
Q4 2021 Feb 14, 2022	BUY	$3.37 - $7.91 $220,590 - $517,764	65,457 Added 629.27%	75,859 $277,000
Q3 2021 Nov 15, 2021	BUY	$7.84 - $12.53 $68,113 - $108,860	8,688 Added 506.88%	10,402 $83,000
Q2 2021 Aug 16, 2021	SELL	$7.55 - $12.95 $47,051 - $80,704	-6,232 Reduced 78.43%	1,714 $19,000
Q1 2021 May 13, 2021	BUY	$7.58 - $18.67 $60,230 - $148,351	7,946 New	7,946 $73,000

Others Institutions Holding VIRX

# of Institutions

Shares Held

9.03M

Call Options Held

10.9K

Put Options Held

400

View Full List

About Viracta Therapeutics, Inc.

Ticker VIRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,558,200
Market Cap $8.26M
Description
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...

More about VIRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Viracta Therapeutics, Inc. Transaction History